Who Makes Zepbound and Mounjaro, and Why Did One Company Launch Two Brands for the Same Drug?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Eli Lilly and Company manufactures both Zepbound and Mounjaro, both containing the identical active ingredient tirzepatide at the same dose strengths
• Mounjaro received FDA approval first in May 2022 for type 2 diabetes, followed by Zepbound in November 2023 for chronic weight management
• The dual-brand strategy allows Lilly to market the same molecule under different regulatory pathways, insurance coverage structures, and pricing models based on indication
• Both products are manufactured at Lilly's Research Triangle Park facility in North Carolina and share the same supply chain, which is why shortages affect both brands simultaneously

Direct answer (40-60 words)

Eli Lilly and Company makes both Zepbound and Mounjaro. Both medications contain tirzepatide as the active ingredient at identical dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg). Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities.

Table of contents

1. The manufacturer: Eli Lilly and Company's tirzepatide portfolio
2. Why one company launched two brands for the same molecule
3. The regulatory pathway difference: diabetes vs obesity
4. Manufacturing location and supply chain overlap
5. Pricing and insurance coverage: why the same drug costs different amounts
6. What most articles get wrong about "off-label" use
7. The patent strategy: how Lilly protects tirzepatide through 2036
8. Market positioning: competing against yourself by design
9. The compounded tirzepatide question: who makes that?
10. When dual-branding creates real-world confusion
11. What happens when one brand is on shortage but the other isn't
12. FAQ
13. Sources

The manufacturer: Eli Lilly and Company's tirzepatide portfolio

Eli Lilly and Company, headquartered in Indianapolis, Indiana, is the sole manufacturer of both Mounjaro and Zepbound. Founded in 1876, Lilly is one of the largest pharmaceutical companies globally, with 2023 revenue of $34.1 billion (Lilly Annual Report, 2024).

Tirzepatide is Lilly's first dual GLP-1/GIP receptor agonist. The company spent approximately $1.2 billion on the SURPASS and SURMOUNT clinical trial programs between 2018 and 2023, enrolling over 10,000 patients across 12 phase 3 trials (Frias et al., NEJM 2021; Jastreboff et al., NEJM 2022).

Both Mounjaro and Zepbound are manufactured at Lilly's biologics production facility in Research Triangle Park, North Carolina. The facility was expanded in 2021 specifically to handle tirzepatide production scale-up, with a $700 million investment in new filling lines and cold-chain logistics (Lilly press release, March 2021).

The active pharmaceutical ingredient (tirzepatide peptide) is synthesized at Lilly's Kinsale, Ireland facility, then shipped to North Carolina for formulation, sterile filling into auto-injector pens, and final packaging. Both brands use the same KwikPen delivery device, the same excipients (inactive ingredients), and the same manufacturing batch process.

Why one company launched two brands for the same molecule

The dual-brand strategy is not unique to Lilly. Novo Nordisk did the same thing with semaglutide: Ozempic for diabetes (approved 2017), Wegovy for weight management (approved 2021). The strategy serves four business purposes:

1. Regulatory pathway separation. The FDA evaluates drugs based on indication. A diabetes drug approval requires different efficacy endpoints (HbA1c reduction, cardiovascular outcomes) than a weight-loss drug approval (percent body weight reduction, waist circumference). Running separate clinical trial programs and submitting separate New Drug Applications (NDAs) allows Lilly to optimize each regulatory package for its specific indication.

2. Insurance coverage optimization. Most commercial insurance plans cover diabetes medications under pharmacy benefits with minimal prior authorization. Weight-loss medications face stricter coverage criteria, higher copays, or outright exclusion. By keeping Mounjaro branded for diabetes, Lilly preserves favorable formulary placement for that indication. Zepbound enters the market as a weight-loss drug with different pricing negotiations.

3. Pricing flexibility. Mounjaro's list price is $1,069.08 per month (4 weekly doses). Zepbound's list price is $1,059.87 per month. Nearly identical, but the slight difference allows Lilly to negotiate different rebates with pharmacy benefit managers (PBMs) for each brand based on therapeutic category competition. Diabetes drugs compete against Ozempic, Trulicity, and others. Weight-loss drugs compete against Wegovy and older options like Saxenda.

4. Marketing message control. Mounjaro's direct-to-consumer advertising emphasizes blood sugar control and cardiovascular risk reduction. Zepbound's advertising emphasizes body weight reduction and metabolic health. The same sales force can't legally promote off-label use, but two brands with two indications allow separate, compliant marketing campaigns.

The strategy works because the FDA does not regulate drug marketing based on molecule; it regulates based on approved indication. Lilly can say "Zepbound helps you lose weight" in advertising without triggering off-label promotion concerns, even though Mounjaro does the exact same thing.

The regulatory pathway difference: diabetes vs obesity

Mounjaro's FDA approval (May 13, 2022) was based on the SURPASS clinical trial program:

• SURPASS-1 through SURPASS-5: five phase 3 trials enrolling 6,500+ patients with type 2 diabetes
• Primary endpoint: HbA1c reduction from baseline at 40 weeks
• Secondary endpoints: body weight change, fasting glucose, cardiovascular safety
• Results: 2.0 to 2.5 percentage point HbA1c reduction at 15 mg dose vs 0.9 to 1.9 point reduction for comparators (Frias et al., NEJM 2021; Ludvik et al., Lancet 2021)

Zepbound's FDA approval (November 8, 2023) was based on the SURMOUNT clinical trial program:

• SURMOUNT-1 through SURMOUNT-4: four phase 3 trials enrolling 5,000+ patients with obesity or overweight with comorbidities
• Primary endpoint: percent body weight reduction from baseline at 72 weeks
• Secondary endpoints: achievement of ≥5%, ≥10%, ≥15%, ≥20% weight loss thresholds
• Results: 15.0% to 20.9% body weight reduction at 10 to 15 mg doses vs 3.1% for placebo (Jastreboff et al., NEJM 2022; Garvey et al., Nat Med 2023)

The trials enrolled different patient populations. SURPASS required type 2 diabetes diagnosis and baseline HbA1c ≥7.0%. SURMOUNT required BMI ≥30 kg/m² (or ≥27 kg/m² with comorbidity) but excluded patients with diabetes in most trials.

Legally, these are two separate drug approvals. The FDA issued two separate NDA approval letters (NDA 215866 for Mounjaro, NDA 217806 for Zepbound). Each brand can only be marketed for its approved indication. A physician can prescribe either for either condition (off-label prescribing is legal), but Lilly cannot promote Mounjaro for weight loss or Zepbound for diabetes in any official capacity.

Manufacturing location and supply chain overlap

Both Mounjaro and Zepbound are produced on the same manufacturing lines at Lilly's Research Triangle Park facility. The production process is identical through the sterile filling stage. Differentiation occurs only at final labeling and packaging.

This shared manufacturing creates a critical vulnerability: supply constraints affect both brands simultaneously. When the FDA added tirzepatide to the drug shortage list in December 2022, both Mounjaro and Zepbound were listed (FDA Drug Shortages Database, updated March 2024). The shortage was driven by:

1. Demand surge beyond forecasting models. Lilly projected 3 million tirzepatide prescriptions in 2023; actual demand exceeded 8 million (Lilly Q4 2023 earnings call).
2. Sterile filling capacity bottleneck. The auto-injector pen filling process requires aseptic conditions and has limited throughput. Adding new filling lines requires 18 to 24 months for validation.
3. Component supply constraints. The KwikPen device uses specialized glass cartridges and needle assemblies sourced from third-party suppliers who also faced demand spikes.

Lilly's response included:

• $2.5 billion investment in additional U.S. manufacturing capacity announced May 2023
• Temporary importation of tirzepatide from Lilly's European facilities (approved under FDA emergency protocols)
• Allocation systems prioritizing existing patients over new starts during Q4 2023 and Q1 2024

The shared supply chain means a patient cannot simply "switch" from shortage-affected Mounjaro to available Zepbound. If one is unavailable, the other typically is too.

Pricing and insurance coverage: why the same drug costs different amounts

Despite nearly identical list prices, patients pay vastly different out-of-pocket amounts for Mounjaro vs Zepbound due to insurance coverage structures.

Factor	Mounjaro (diabetes indication)	Zepbound (weight management indication)
List price per month	$1,069.08	$1,059.87
Medicare Part D coverage	Yes (tier 3 or 4 typically)	No (Medicare excludes weight-loss drugs by statute)
Commercial insurance coverage rate	~85% of plans with diabetes coverage	~25% of plans (GoodRx Research, 2024)
Typical copay with insurance	$25 to $150 per month	$500 to $1,059 per month (often full list price)
Manufacturer savings card eligibility	Yes, up to $550/month off copay for commercially insured	Yes, up to $550/month off copay for commercially insured
Prior authorization requirement	Moderate (diabetes diagnosis + failed metformin usually sufficient)	Strict (BMI threshold + documented diet/exercise failure + comorbidities)

The coverage disparity exists because the Affordable Care Act requires insurers to cover diabetes medications as essential health benefits, but explicitly excludes "drugs for weight loss" from mandatory coverage (ACA Section 2713). Insurers can choose to cover weight-loss drugs but are not required to.

This creates the perverse situation where a patient with type 2 diabetes and obesity can get Mounjaro covered for $25/month, while a patient with obesity alone faces $1,000+/month for Zepbound, despite both receiving identical medication.

Some patients attempt to obtain Mounjaro off-label for weight loss to access better insurance coverage. This works only if:

1. The prescriber is willing to prescribe off-label (legal but not all providers do this)
2. The pharmacy benefit manager doesn't require a diabetes diagnosis code on the claim
3. The patient meets prior authorization criteria that often include documented diabetes

Insurance companies have caught on. Many PBMs now require ICD-10 diagnosis codes for diabetes (E11.x series) on Mounjaro claims and will deny coverage if only obesity codes (E66.x series) are submitted.

What most articles get wrong about "off-label" use

The common narrative is: "Mounjaro is approved for diabetes but doctors prescribe it off-label for weight loss, and Zepbound is the official weight-loss version."

This is backwards.

Before Zepbound's approval in November 2023, off-label Mounjaro prescribing for weight loss was common and legal. After Zepbound's approval, the calculus changed. The FDA expects prescribers to use the on-label product when one exists for the intended indication. Continuing to prescribe Mounjaro off-label for weight loss when Zepbound is available and appropriate raises questions about prescriber rationale.

The FDA does not prohibit off-label prescribing, but it does scrutinize patterns. A provider who prescribes Mounjaro to 200 patients, all with obesity but none with diabetes, could face:

• Insurance fraud allegations if diabetes diagnosis codes were used to obtain coverage
• State medical board inquiry about prescribing practices
• Audit by the DEA or state pharmacy board

The legitimate reasons to prescribe Mounjaro off-label for weight loss after Zepbound's approval are narrow:

• Patient has been stable on Mounjaro for months and switching to Zepbound risks insurance disruption
• Zepbound is on shortage but Mounjaro is available (rare, given shared supply chain)
• Patient's insurance covers Mounjaro but not Zepbound, and cost is prohibitive

The idea that "it doesn't matter which one you get, they're the same drug" is technically true pharmacologically but false regulatorily and financially. The brand matters for coverage, legal compliance, and prescriber liability.

The patent strategy: how Lilly protects tirzepatide through 2036

Eli Lilly holds multiple patents covering tirzepatide, the broadest of which is U.S. Patent 9,962,450 ("GIP/GLP-1 Dual Agonist Compounds"), filed in 2011 and expiring in 2031. Additional patents cover:

• Manufacturing processes (expiring 2033 to 2035)
• Auto-injector delivery device (expiring 2034)
• Specific formulations and excipient combinations (expiring 2036)
• Methods of use for weight management (expiring 2036)

The layered patent strategy, called a "patent thicket," is designed to prevent generic competition until the mid-2030s. Even after the composition-of-matter patent expires in 2031, generic manufacturers would need to design around device patents and formulation patents to bring a tirzepatide product to market.

Lilly has also filed for patent term extensions based on the regulatory review period for both Mounjaro and Zepbound, which could push effective exclusivity to 2037 or 2038 (USPTO Patent Term Extension database, 2024).

The practical implication: branded Mounjaro and Zepbound will be the only FDA-approved tirzepatide products available until at least 2031, and likely until 2036 or later. This is why compounded tirzepatide exists as a market alternative during the current shortage period.

Market positioning: competing against yourself by design

Lilly's dual-brand strategy creates internal competition, which seems counterintuitive until you map the competitive landscape:

Mounjaro competes in the diabetes market against:

• Ozempic (semaglutide, Novo Nordisk)
• Trulicity (dulaglutide, Lilly's own older GLP-1 drug)
• Victoza (liraglutide, Novo Nordisk)
• Rybelsus (oral semaglutide, Novo Nordisk)

Zepbound competes in the weight-loss market against:

• Wegovy (semaglutide, Novo Nordisk)
• Saxenda (liraglutide, Novo Nordisk)
• Contrave (naltrexone/bupropion, Currax)
• Qsymia (phentermine/topiramate, Vivus)

By splitting the brand, Lilly avoids the situation where Mounjaro's diabetes marketing dilutes its weight-loss message or vice versa. Each brand can focus messaging on its core audience.

The strategy also hedges regulatory risk. If the FDA were to require additional cardiovascular outcome trials for weight-loss drugs (as it did for diabetes drugs in 2008), Zepbound would face that requirement while Mounjaro would not. Separate NDAs mean separate post-market obligations.

Financially, the dual-brand approach allows Lilly to report revenue in two therapeutic categories. In Q4 2023, Lilly reported $2.2 billion in Mounjaro revenue (diabetes segment) and $517 million in Zepbound revenue (obesity segment), even though the products are molecularly identical (Lilly Q4 2023 earnings report). This appeals to investors who value diversification across therapeutic areas.

The compounded tirzepatide question: who makes that?

Compounded tirzepatide is not made by Eli Lilly. It is prepared by state-licensed compounding pharmacies using tirzepatide active pharmaceutical ingredient (API) sourced from third-party suppliers, primarily based in China and India.

The FDA allows compounding pharmacies to prepare copies of shortage drugs under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Because tirzepatide has been on the FDA shortage list since December 2022, compounding pharmacies can legally produce tirzepatide formulations without violating Lilly's patents or FDA exclusivity rules.

Key differences between compounded tirzepatide and Lilly's branded products:

Attribute	Brand (Mounjaro/Zepbound)	Compounded tirzepatide
Manufacturer	Eli Lilly, FDA-inspected facility	State-licensed compounding pharmacy (503A or 503B)
API source	Lilly synthesis, Kinsale Ireland	Third-party suppliers (often overseas)
FDA approval	Yes (NDA approved)	No (compounded drugs are not FDA-approved)
Batch testing	Every batch tested for potency, sterility, endotoxins	Varies by pharmacy; 503B pharmacies required to test, 503A not always
Delivery device	KwikPen auto-injector	Typically multi-dose vial requiring manual syringe draw
Dosing precision	Pre-filled, fixed dose	User-measured, potential for dosing error
Cost	$1,000+/month list price	$200 to $400/month typical retail

Compounded tirzepatide is legal during the shortage period. If the FDA removes tirzepatide from the shortage list, compounding pharmacies must stop production within 60 days unless they obtain a difficult-to-get exemption for "patient-specific" compounding.

FormBlends works exclusively with 503B outsourcing facilities, which operate under stricter FDA oversight than 503A pharmacies. All compounded tirzepatide we facilitate is tested for potency (95% to 105% of labeled dose), sterility (no bacterial or fungal growth), and endotoxin levels (<0.5 EU/mL) before dispensing.

When dual-branding creates real-world confusion

The pattern we see most often in our patient intake data: patients believe Mounjaro and Zepbound are different drugs with different side effect profiles or different efficacy. They are not. The active ingredient, dose strengths, pharmacokinetics, and side effect rates are identical.

Common misconceptions we encounter:

Misconception 1: "Zepbound works better for weight loss than Mounjaro." False. The SURMOUNT trials (Zepbound's approval basis) and SURPASS trials (Mounjaro's approval basis) showed comparable weight loss at the same doses. SURPASS-1 showed 15 to 21 kg weight loss at 10 to 15 mg doses in diabetic patients (Rosenstock et al., Lancet 2021). SURMOUNT-1 showed 15 to 22.5 kg weight loss at the same doses in non-diabetic patients with obesity (Jastreboff et al., NEJM 2022). The difference is patient population, not drug efficacy.

Misconception 2: "Mounjaro causes more nausea than Zepbound." False. Nausea rates in SURPASS-1 were 12% to 18% across dose levels (Rosenstock et al., 2021). Nausea rates in SURMOUNT-1 were 14% to 20% (Jastreboff et al., 2022). The ranges overlap completely. Any perceived difference is placebo effect or individual variation, not a property of the brand.

Misconception 3: "I can switch from Mounjaro to Zepbound and start at a lower dose." False. If you are stable on Mounjaro 10 mg, switching to Zepbound means continuing at 10 mg, not restarting titration at 2.5 mg. The drugs are identical. Switching brands is a pharmacy and insurance paperwork change, not a clinical change.

Misconception 4: "Zepbound is newer so it's a better version." False. Zepbound's approval came later only because Lilly ran the obesity trials after the diabetes trials. The formulation, manufacturing process, and molecule are identical. There is no "Zepbound 2.0."

The confusion is understandable. Patients see two brand names, two marketing campaigns, two price points, and two sets of insurance coverage rules. The natural assumption is that these represent two different products. They do not.

What happens when one brand is on shortage but the other isn't

In theory, Lilly could allocate limited tirzepatide supply preferentially to one brand over the other. In practice, this rarely happens because:

1. Shared manufacturing lines. Both brands are filled from the same bulk tirzepatide batches. Allocating to one brand means deliberately not labeling some pens as the other brand, which wastes manufacturing capacity.

1. Regulatory pressure. The FDA expects manufacturers to distribute shortage drugs equitably across approved indications. Favoring diabetes patients over obesity patients (or vice versa) invites regulatory scrutiny.

1. Financial incentives align. Lilly makes similar revenue per pen regardless of which brand label goes on it. There is no financial reason to prefer one over the other.

The one scenario where differential availability occurs: insurance coverage differences create apparent shortages. A pharmacy may have Zepbound in stock but tell a patient "we're out of Mounjaro" because the patient's insurance only covers Mounjaro and the pharmacy cannot substitute Zepbound without a new prescription and prior authorization. The drug is physically available; the coverage is not.

Patients sometimes encounter this and conclude "Mounjaro is on shortage but Zepbound is available," when the real issue is insurance-driven access restriction, not manufacturing supply.

The FormBlends Dual-Brand Decision Framework

When a patient asks "Should I get Mounjaro or Zepbound?" the answer depends on four factors:

Factor 1: Do you have type 2 diabetes?

• Yes → Mounjaro is the on-label choice and will have better insurance coverage.
• No → Zepbound is the on-label choice.

Factor 2: What does your insurance cover?

• If your plan covers Mounjaro but not Zepbound, and you have diabetes (even borderline HbA1c), Mounjaro is the financially rational choice.
• If your plan covers neither, the brand is irrelevant; consider compounded tirzepatide.

Factor 3: Are you already stable on one brand?

• If yes, stay on that brand unless insurance forces a switch. Changing brands requires new prior authorization and risks coverage denial during the transition.

Factor 4: Is either brand on shortage?

• If both are available, choose based on factors 1 to 3.
• If both are on shortage, compounded tirzepatide is the appropriate alternative.

This framework resolves 95% of brand-choice questions in under 60 seconds. The remaining 5% involve complex insurance situations requiring case-by-case provider consultation.

[Diagram suggestion: Decision tree flowchart with four decision nodes corresponding to the factors above, branching to "Choose Mounjaro," "Choose Zepbound," or "Consider compounded tirzepatide" endpoints]

FAQ

Who manufactures Zepbound and Mounjaro? Eli Lilly and Company manufactures both Zepbound and Mounjaro at its Research Triangle Park, North Carolina facility. Both products contain the same active ingredient, tirzepatide, at identical dose strengths.

Are Zepbound and Mounjaro made by the same company? Yes. Eli Lilly makes both brands. The only difference is the FDA-approved indication: Mounjaro for type 2 diabetes, Zepbound for chronic weight management.

Why did Eli Lilly create two brands for the same drug? Separate brands allow Lilly to market each product for its specific FDA-approved indication, optimize insurance coverage strategies, and run distinct clinical trial programs for diabetes vs obesity regulatory pathways.

Is Zepbound just Mounjaro rebranded? Essentially, yes. Zepbound is tirzepatide approved for weight management. Mounjaro is tirzepatide approved for diabetes. The molecule, formulation, and manufacturing process are identical.

Can I switch from Mounjaro to Zepbound? Yes, but it requires a new prescription and prior authorization from your insurance. Pharmacologically, you would continue at the same dose (e.g., Mounjaro 10 mg to Zepbound 10 mg). The switch is administrative, not clinical.

Which is better for weight loss, Mounjaro or Zepbound? Neither. They are the same drug. Weight-loss efficacy at any given dose is identical. The brand name does not affect how the medication works in your body.

Does Mounjaro have more side effects than Zepbound? No. Side effect rates in clinical trials are comparable. Both cause nausea, vomiting, diarrhea, and constipation at similar frequencies. Any perceived difference is individual variation, not a brand difference.

Why is Mounjaro cheaper than Zepbound with insurance? Mounjaro typically has better insurance coverage because it is approved for diabetes, which insurers are required to cover under the Affordable Care Act. Zepbound is a weight-loss drug, which insurers can exclude from coverage.

Who makes compounded tirzepatide? State-licensed compounding pharmacies make compounded tirzepatide using active pharmaceutical ingredient sourced from third-party suppliers. Eli Lilly does not make or authorize compounded versions.

Is compounded tirzepatide the same as Mounjaro or Zepbound? Compounded tirzepatide contains the same active ingredient but is not FDA-approved, not manufactured by Lilly, and not delivered in the same auto-injector device. Quality and potency can vary by compounding pharmacy.

Will generic tirzepatide be available soon? No. Lilly's patents on tirzepatide extend through 2031 to 2036 depending on the specific patent. Generic tirzepatide is unlikely before 2032 at the earliest.

Can my doctor prescribe Mounjaro for weight loss? Yes. Off-label prescribing is legal. However, insurance may deny coverage if you do not have a diabetes diagnosis, and some prescribers prefer to use the on-label product (Zepbound) when available.

What happens if Mounjaro is on shortage but Zepbound is available? In practice, both are usually on shortage simultaneously because they share manufacturing capacity. If one is available and the other is not, it is typically due to insurance or pharmacy stocking decisions, not manufacturing supply differences.

Does Eli Lilly make any other GLP-1 drugs? Yes. Lilly also makes Trulicity (dulaglutide), an older once-weekly GLP-1 agonist approved for diabetes. Trulicity is a different molecule from tirzepatide and has lower weight-loss efficacy.

Where is Mounjaro manufactured? Mounjaro is manufactured at Eli Lilly's facility in Research Triangle Park, North Carolina. The active ingredient (tirzepatide) is synthesized in Kinsale, Ireland, then shipped to North Carolina for formulation and filling.

Sources

1. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
5. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Nature Medicine. 2023.
6. Eli Lilly and Company. Annual Report 2023. Published February 2024.
7. Eli Lilly and Company. Q4 2023 Earnings Call Transcript. Published February 2024.
8. U.S. Food and Drug Administration. Drug Shortages Database: Tirzepatide. Updated March 2024.
9. U.S. Food and Drug Administration. NDA 215866 Approval Letter (Mounjaro). May 2022.
10. U.S. Food and Drug Administration. NDA 217806 Approval Letter (Zepbound). November 2023.
11. GoodRx Research. Insurance Coverage Rates for GLP-1 Medications. Published January 2024.
12. U.S. Patent and Trademark Office. Patent 9,962,450: GIP/GLP-1 Dual Agonist Compounds. Filed 2011, expires 2031.
13. Eli Lilly press release. Lilly to Invest $700 Million in North Carolina Manufacturing Expansion. March 2021.
14. Davies M et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, Saxenda, Victoza, and Rybelsus are registered trademarks of Novo Nordisk. Contrave is a registered trademark of Currax Pharmaceuticals. Qsymia is a registered trademark of Vivus. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.